Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases (CRLM)
2026年4月27日 更新者：Meng Qiu
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
研究概览
地位
主动，不招人
条件
详细说明
This study aims to retrospectively analyze the status and spatial heterogeneity of the tumor microenvironment (TME) in liver metastases from patients with CRLM, as well as the association between HGPs at the tumor-liver interface and postoperative recurrence following resection of liver metastases.
Furthermore, this study seeks to explore the underlying mechanisms through which HGPs influence patient prognosis.
研究类型
观察性的
注册 (估计的)
64
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital of Sichuan University
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
This study enrolled patients with CRLM who underwent R0 resection.
描述
Inclusion Criteria:
- Patients with CRLM who underwent R0 resection
- Histologically or cytologically confirmed CRLM
- Have sufficient liver metastasis tissue specimens available for analysis
- Complete treatment and follow-up records
Exclusion Criteria:
- Patients did not undergo R0 resection
- Postoperative specimens were unavailable
- Clinical data were incomplete.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
patients with CRLM who underwent R0 resection
According to the 2017 guidelines on histopathological growth patterns of liver metastases, HGPs are primarily classified into three types: the desmoplastic histopathological growth pattern (dHGP), the replacement histopathological growth pattern (rHGP), and the pushing histopathological growth pattern (pHGP).
The tumor-liver interface was independently delineated by two pathologists using QuPath software, and distinct HGPs at the tumor-liver interface were identified.
Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E).Multiplex immunohistochemistry (mIHC) staining was performed on FFPE sections of liver metastases using two panels (Panel 1: CD4, CD8A, Foxp3, PD-L1, Panck; Panel 2: CD68, CD163, FAP-α, α-SMA, Panck), encompassing a total of nine immune cell markers.
|
Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
OS(Overall survival)
大体时间：OS is defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up, assessed up to 100 months.
|
OS was defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up.
|
OS is defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up, assessed up to 100 months.
|
|
RFS (Recurrence-free Survival)
大体时间：From the date of liver resection until the first occurrence of a measurable recurrence of the disease, or until death due to any cause (whichever occurs first), the assessment period can be up to 100 months.
|
The definition of recurrence-free survival is the time from the liver surgery to the first imaging evidence showing disease recurrence or death due to any cause, whichever occurs first.
|
From the date of liver resection until the first occurrence of a measurable recurrence of the disease, or until death due to any cause (whichever occurs first), the assessment period can be up to 100 months.
|
|
HGPs (Histopathological Growth Patterns)
大体时间：From the completion of HE staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
|
The histopathological growth pattern of the tumor-liver interface.
|
From the completion of HE staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
|
|
TME (Tumor Microenvironment)
大体时间：From the completion of mIHC staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
|
Multiplex immunohistochemistry (mIHC) staining was performed on FFPE sections of liver metastases using two panels (Panel 1: CD4, CD8A, Foxp3, PD-L1, Panck; Panel 2: CD68, CD163, FAP-α, α-SMA, Panck), encompassing a total of nine immune cell markers.
Using QuPath pathology imaging software, tissue sections were divided into the tumor center (defined as regions >500 μm from the liver-tumor interface) and the invasive tumor front (defined as a 1 mm region extending 500 μm on either side of the liver-tumor interface).
Quantitative analysis of immune cell populations was performed in the tumor center, the invasive tumor front, and regions corresponding to different histopathological growth patterns.
|
From the completion of mIHC staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Stremitzer S, Vermeulen P, Graver S, Kockx M, Dirix L, Yang D, Zhang W, Stift J, Wrba F, Gruenberger T, Lenz HJ, Scherer SJ. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. Br J Cancer. 2020 May;122(10):1518-1524. doi: 10.1038/s41416-020-0812-z. Epub 2020 Mar 24.
- Latacz E, Hoppener D, Bohlok A, Leduc S, Tabaries S, Fernandez Moro C, Lugassy C, Nystrom H, Bozoky B, Floris G, Geyer N, Brodt P, Llado L, Van Mileghem L, De Schepper M, Majeed AW, Lazaris A, Dirix P, Zhang Q, Petrillo SK, Vankerckhove S, Joye I, Meyer Y, Gregorieff A, Roig NR, Vidal-Vanaclocha F, Denis L, Oliveira RC, Metrakos P, Grunhagen DJ, Nagtegaal ID, Mollevi DG, Jarnagin WR, D'Angelica MI, Reynolds AR, Doukas M, Desmedt C, Dirix L, Donckier V, Siegel PM, Barnhill R, Gerling M, Verhoef C, Vermeulen PB. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br J Cancer. 2022 Oct;127(6):988-1013. doi: 10.1038/s41416-022-01859-7. Epub 2022 Jun 1.
- van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grunhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nystrom H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.
- Zhang A, Zhang Y, Xu J, Zhu R, Liang T, Guo L. Molecular landscape of colorectal cancer liver metastasis: Tumor microenvironment heterogeneity and driver inference. Crit Rev Oncol Hematol. 2025 Dec;216:104946. doi: 10.1016/j.critrevonc.2025.104946. Epub 2025 Sep 12.
- Liang JY, Xi SY, Shao Q, Yuan YF, Li BK, Zheng Y, Wang DS, Wu XJ, Ding PR, Chen G, Li LR, Wang FH, Wang ZQ, Pan ZZ, Xu RH, Li YH. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. Cancer Immunol Immunother. 2020 Dec;69(12):2623-2634. doi: 10.1007/s00262-020-02632-6. Epub 2020 Jun 29.
- He Y, Han Y, Fan AH, Li D, Wang B, Ji K, Wang X, Zhao X, Lu Y. Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases. J Transl Med. 2022 Oct 4;20(1):454. doi: 10.1186/s12967-022-03667-2.
- Hoppener DJ, Nierop PMH, Hof J, Sideras K, Zhou G, Visser L, Gouw ASH, de Jong KP, Sprengers D, Kwekkeboom J, Vermeulen PB, Grunhagen DJ, Verhoef C. Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis. Br J Cancer. 2020 Jul;123(2):196-206. doi: 10.1038/s41416-020-0881-z. Epub 2020 May 18.
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2018年1月1日
初级完成 (估计的)
2030年12月30日
研究完成 (估计的)
2030年12月30日
研究注册日期
首次提交
2026年4月27日
首先提交符合 QC 标准的
2026年4月27日
首次发布 (实际的)
2026年5月4日
研究记录更新
最后更新发布 (实际的)
2026年5月4日
上次提交的符合 QC 标准的更新
2026年4月27日
最后验证
2026年4月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Approval No. 2021, 2024
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
未定
IPD 计划说明
First of all, there is a lack of sufficient funds or personnel to anonymize and maintain the data for a long time, such as the original imaging documents, which are difficult to organize compliance.
Second, this study was an early exploratory study with small data size and high risk of identification.
Finally, summary results are available after publication, and the data will be reassessed 5 years after the end of the study.
研究数据/文件
-
统计分析计划
信息标识符：qiumeng@wchscu.cn信息评论：Survival analysis was estimated using the Kaplan-Meier method and compared using the log-rank test. Quantitative data regarding the immune microenvironment were compared using the t-test or the Mann-Whitney U test, as appropriate. Changes between initial resection and secondary resection were analyzed using the nonparametric test for two paired samples. The endpoints of this study included patient clinical outcomes (OS and PFS), spatial distribution differences of immune cells within TME of liver metastases, distribution patterns of HGPs and their correlation with survival, and analysis of the immune microenvironment in relation to HGPs.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.